Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7123914 | 0.98 | LMNA (0.45) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| Hydrazine SCHEMBL7121815 | 0.96 | LMNA (0.44) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| Guanidine SCHEMBL7115879 | 0.89 | LMNA (0.41) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| SCHEMBL7225377 | 0.86 | KDM4E (0.40) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| Pimagedine SCHEMBL7117351 | 0.83 | LMNA (0.41) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| SCHEMBL7122109 | 0.80 | LMNA (0.36) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| T-Butylacetic Acid SCHEMBL10005013 | 0.80 | LMNA (0.41) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| T-Butylacetic Acid SCHEMBL21570799 | 0.80 | LMNA (0.41) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| SCHEMBL7122106 | 0.80 | LMNA (0.36) | LMNAMAPTTSHRCYP1A2GRIA1 | |
| SCHEMBL10505577 | 0.79 | MAPT (0.46) | LMNAMAPTTSHRCYP1A2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 924 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438164-B | Method for preparing 3, 6-diaminopyrazine-2, 5-dicarboxylic acid and synthetic intermediate thereof | HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-120114996-A | Composite nanofiltration membrane with high permeability and pollution resistance as well as preparation method and application thereof | 同济大学 | 2025-06-10 | — | — | CN | claimed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| US-12240852-B2 | Co-crystals, method and apparatus for forming the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-04 | — | — | US | claimed |
| US-20240025864-A1 | METHOD FOR PREPARING 3,6-DIAMINOPYRAZINE-2,5-DICARBOXYLIC ACID AND SYNTHETIC INTERMEDIATE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | claimed |
| EP-4242209-A1 | METHOD FOR PREPARING 3,6-DIAMINOPYRAZINE-2,5-DICARBOXYLIC ACID AND SYNTHETIC INTERMEDIATE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116438164-A | Method for preparing 3, 6-diaminopyrazine-2, 5-dicarboxylic acid and synthetic intermediate thereof | 杭州中美华东制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| WO-2022096015-A1 | METHOD FOR PREPARING 3,6-DIAMINOPYRAZINE-2,5-DICARBOXYLIC ACID AND SYNTHETIC INTERMEDIATE THEREOF | 杭州中美华东制药有限公司 | 2022-05-12 | — | — | WO | claimed |
| US-5580681-A | SOLID ELECTROLYTE, ORGANIC ANODE, SOLID CATHODE | E.C.R.-ELECTRO-CHEMICAL RESEARCH LTD. (IL) | 1996-12-03 | — | — | US | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0390540-B1 | Process for preparing an organic compound thin film for an optical device | SHARP KK (JP) | 1994-08-03 | — | — | EP | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
| US-5084302-A | PROCESS FOR PREPARING AN ORGANIC COMPOUND THIN FILM FOR AN OPTICAL DEVICE | SHARP KABUSHIKI KAISHA (JP) | 1992-01-28 | — | — | US | claimed |
| EP-0390540-A2 | Process for preparing an organic compound thin film for an optical device | SHARP KABUSHIKI KAISHA (JP) | 1990-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025864-A1 | METHOD FOR PREPARING 3,6-DIAMINOPYRAZINE-2,5-DICARBOXYLIC ACID AND SYNTHETIC INTERMEDIATE THEREOF | DPYD, GART, DHODH | LMNA 3148/4885MAPT 997/4885TSHR 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.